PROMUS Element Stent
Posted on: November 3, 2009 user submitted | Views: | Comment
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element¿ Everolimus-Eluting Coronary Stent System, the Company¿s third-generation drug-eluting stent (DES) technology. The PROMUS Element system incorporates a unique platinum chromium alloy with an innovative stent design and an advanced catheter delivery system. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bostonscientific/36501/
